BACKGROUND: Busulfan is used in preparative regimens prior to stem cell transplantation in pediatric patients. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. To date, only polymorphisms in genes encoding for glutathione-S-transferases were studied, but could only explain a small portion of the variability in PK. AIM: To investigate the effect of seven genetic markers on busulfan clearance and the effect of ontogenesis on these genetic variants in a pediatric population. MATERIALS & METHODS: In an earlier study of our group seven genetic markers in GSTA1, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8 were associated with busulfan clearance in adult patients. Eighty four pediatric patients were genotyped for these markers and genotype was associated with busulfan clearance. RESULTS & CONCLUSION: GSTA1 and CYP39A1 were found to be associated with busulfan clearance. When combined, the two haplotypes explained 17% of the variability in busulfan clearance. Furthermore, the effect of GSTA1 haplotype on clearance was dependent on age.
BACKGROUND:Busulfan is used in preparative regimens prior to stem cell transplantation in pediatric patients. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. To date, only polymorphisms in genes encoding for glutathione-S-transferases were studied, but could only explain a small portion of the variability in PK. AIM: To investigate the effect of seven genetic markers on busulfan clearance and the effect of ontogenesis on these genetic variants in a pediatric population. MATERIALS & METHODS: In an earlier study of our group seven genetic markers in GSTA1, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8 were associated with busulfan clearance in adult patients. Eighty four pediatric patients were genotyped for these markers and genotype was associated with busulfan clearance. RESULTS & CONCLUSION:GSTA1 and CYP39A1 were found to be associated with busulfan clearance. When combined, the two haplotypes explained 17% of the variability in busulfan clearance. Furthermore, the effect of GSTA1 haplotype on clearance was dependent on age.
Authors: Merrie Mosedale; Yanwei Cai; John Scott Eaddy; Robert W Corty; Manisha Nautiyal; Paul B Watkins; William Valdar Journal: Toxicol Sci Date: 2019-12-01 Impact factor: 4.849
Authors: Kathryn L Bradford; Siyu Liu; Maja Krajinovic; Marc Ansari; Elizabeth Garabedian; John Tse; Xiaoyan Wang; Kit L Shaw; H Bobby Gaspar; Fabio Candotti; Donald B Kohn Journal: Biol Blood Marrow Transplant Date: 2020-07-09 Impact factor: 5.742
Authors: Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson Journal: Expert Opin Drug Metab Toxicol Date: 2017-08-17 Impact factor: 4.481
Authors: Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari Journal: J Pers Med Date: 2021-04-26
Authors: Marc Ansari; Patricia Huezo-Diaz Curtis; Chakradhara Rao S Uppugunduri; Mohammed Aziz Rezgui; Tiago Nava; Vid Mlakar; Laurence Lesne; Yves Théoret; Yves Chalandon; Lee L Dupuis; Tao Schechter; Imke H Bartelink; Jaap J Boelens; Robbert Bredius; Jean-Hugues Dalle; Saba Azarnoush; Petr Sedlacek; Victor Lewis; Martin Champagne; Christina Peters; Henrique Bittencourt; Maja Krajinovic Journal: Oncotarget Date: 2017-08-27
Authors: Ahmed El-Serafi; Rui He; Wenyi Zheng; Fadwa Benkossou; Sandra Oerther; Ying Zhao; Karin Mellgren; Britt Gustafsson; Carsten Heilmann; Jukka Kanerva; Kourosh Lotfi; Jacek Toporski; Mikael Sundin; Martin Höglund; Jonas Mattsson; Ibrahim El-Serafi; Moustapha Hassan Journal: Bone Marrow Transplant Date: 2020-10-21 Impact factor: 5.483